Lipigon Pharmaceuticals AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 0.357 million. Revenue was SEK 1.21 million compared to SEK 0.078 million a year ago. Net loss was SEK 4.87 million compared to SEK 6.84 million a year ago. Basic loss per share from continuing operations was SEK 0.06 compared to SEK 0.36 a year ago.
For the nine months, sales was SEK 16.41 million. Revenue was SEK 17.33 million compared to SEK 0.352 million a year ago. Net loss was SEK 4.57 million compared to SEK 28.51 million a year ago. Basic loss per share from continuing operations was SEK 0.06 compared to SEK 2.22 a year ago.